AMARIN CORP PLC -ADR (AMRN) Stock News
NASDAQ:AMRN - Nasdaq - US0231114044 - ADR - Currency: USD
AMRN Latest News, Press Relases and Analysis
KURA Stock Rises More Than 15% This Past Week: Here's Why
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
Action Taken to Maintain Company’s Nasdaq Listing...
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.
Mentions: GSK
Wall Street ends up with Nvidia, appeals court reinstates Trump tariffs
NEW YORK (Reuters) -U.S. stocks ended higher on Thursday as shares of Nvidia gained after its quarterly results, while investors digested a late-afternoon court ruling that reinstated the most sweeping of President Donald Trump's tariffs. The appeals court ruling came a day after a trade court had ordered an immediate block on the tariffs. Trading was choppy for much of the day and indexes ended well off their highs of the session, however, with investors trying to digest the rulings and as shares of Salesforce fell 3.3%.
RCKT Stock Tanks on Patient Death in Danon Disease Study
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.
ARMP Soars 72% in a Month Following Infectious Disease Study Success
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
Amarin Reports First Quarter 2025 Financial Results
-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and...
Amarin Reports First Quarter 2025 Financial Results
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of...
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call...
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
Action Taken to Maintain Company’s Nasdaq Listing
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
Amarin announced the appointment of JEC Capital Partners' Michael Torok to the Company's Board of Directors. ...
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
– Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action and Utility as A Complementary Therapy for Residual Risk Reduction in Combination with Statins in Important Patient Sub-Categories –